{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/cvd-risk-assessment-management/goals-outcome-measures/nice-quality-standards/","result":{"pageContext":{"chapter":{"id":"a72588c2-75b2-5fb4-8a3b-3a4ee9deb056","slug":"nice-quality-standards","fullItemName":"NICE quality standards","depth":2,"htmlHeader":"<!-- begin field 1ac62501-bc60-4ba7-8640-949f41775935 --><h2>NICE quality standards</h2><!-- end field 1ac62501-bc60-4ba7-8640-949f41775935 -->","summary":null,"htmlStringContent":"<!-- begin item 434a7fe4-ea88-4548-85cb-8929eafdf4c9 --><!-- begin field 233f03e0-8d2a-4587-9005-73af933fa01d --><ul><li>Adults under 85 years with an estimated increased risk of cardiovascular disease (CVD) are offered a full formal risk assessment using the QRISKÂ tool.</li><li>Adults with a 10-year risk of CVD of 10% or more are assessed for secondary causes before any offer of statin therapy.</li><li>Adults with a 10-year risk of CVD of 10% or more receive advice on lifestyle changes before any offer of statin therapy.</li><li>Adults with a 10-year risk of CVD of 10% or more for whom lifestyle changes are ineffective or inappropriate, discuss the risks and benefits of starting statin therapy with their healthcare professional.</li><li>Adults choosing statin therapy for the primary prevention of CVD are offered atorvastatin 20 mg.</li><li>Adults with newly diagnosed CVD are offered atorvastatin 80 mg.</li><li>Adults on a high-intensity statin who have side effects are offered a lower dose or an alternative statin.</li><li>Adults on a high-intensity statin have a repeat measurement of lipids and liver transaminases after 3 months of treatment.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/cvd-risk-assessment-management/references/\">NICE, 2015</a>]</p><!-- end field 233f03e0-8d2a-4587-9005-73af933fa01d --><!-- end item 434a7fe4-ea88-4548-85cb-8929eafdf4c9 -->","topic":{"id":"523d2a2f-e844-578d-a561-3be5cbca9b75","topicId":"f6d3b04f-1af7-4be9-8156-7728560d7626","topicName":"CVD risk assessment and management","slug":"cvd-risk-assessment-management","lastRevised":"Last revised in August 2020","chapters":[{"id":"7b4828f7-b87a-5825-8965-8fdd9129683e","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"e7373cf1-b9a1-5687-9711-2cb9d9c89c69","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"792673f1-3d99-54ef-99fe-bba0e1a561a8","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"b2dea30b-fe5c-5016-a74a-657f491fbc6d","slug":"changes","fullItemName":"Changes"},{"id":"78c4178a-c12b-5c09-b381-a13caf2b0555","slug":"update","fullItemName":"Update"}]},{"id":"a448bfdb-c0ae-515d-94a0-ff7ca675cdb6","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"44aa879e-615a-5bce-88b8-8723ea0ccd5e","slug":"goals","fullItemName":"Goals"},{"id":"6fc1588f-7ff7-56a8-99ea-47cc099b05d5","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"1171d2a1-75d7-533d-b720-0492fc8b1eb3","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"a295e1e8-68f8-5f7f-9079-8b86314aae02","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"80b984d3-485b-5103-b839-49a12de3708b","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"a72588c2-75b2-5fb4-8a3b-3a4ee9deb056","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"7f7061ef-3615-572d-b80c-49d0441b7029","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"7a402468-6c9d-5c65-aa94-ac4fba3efa6f","slug":"definition-of-cvd","fullItemName":"Definition of CVD"},{"id":"86b5e37a-5729-5a1a-8cdb-ce876c2f63ff","slug":"burden-of-cvd","fullItemName":"Burden of CVD"},{"id":"564a5209-6b9c-5f0d-b4e2-44fffe6a13e2","slug":"risk-factors-for-cvd","fullItemName":"Risk factors for CVD"},{"id":"95b341d8-0988-5dcd-9b67-e51b4e310ab8","slug":"strategies-for-cvd-prevention","fullItemName":"Strategies for CVD prevention"}]},{"id":"7ef7e02f-cdf3-5561-87d6-387b8c85c6fe","fullItemName":"Management","slug":"management","subChapters":[{"id":"e351979f-6e51-53cf-9377-6933a02382e6","slug":"cvd-risk-assessment","fullItemName":"Scenario: CVD risk assessment"},{"id":"fe019c79-fed9-53d2-872f-da771bf12db0","slug":"cvd-risk-less-than-10percent","fullItemName":"Scenario: CVD risk less than 10%"},{"id":"7815dd8b-1e90-5da1-8f71-d11a3b4d0454","slug":"cvd-risk-10percent-or-more","fullItemName":"Scenario: CVD risk 10% or more"}]},{"id":"4bca1eaa-45f6-5ef6-8e61-9fcdd7be2974","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"4365c311-267f-5090-b1a7-5ca71f0a5e8b","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"e8349012-8164-5323-bd10-3c52e461fbd4","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"09e44952-956e-5e91-9f5b-b584c9c7340f","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"c76818be-b774-5f66-badd-b8b17ccd0eef","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"4a06dccb-9327-5792-a92c-1c8278cab678","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"ff5c3303-e844-5444-9b71-dbe2fc774f83","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"7a5af289-d6e5-5ded-92b0-696749f9ff11","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"a448bfdb-c0ae-515d-94a0-ff7ca675cdb6","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}